Drug Profile
Research programme: neurodegenerative disorder therapies - Cerecin
Alternative Names: AC-0523; AC-8632Latest Information Update: 18 Oct 2018
Price :
$50
*
At a glance
- Originator Accera
- Developer Cerecin; Neuera Pharmaceuticals
- Class Small molecules
- Mechanism of Action Acetyl-CoA carboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Huntington's disease; Parkinson's disease
Most Recent Events
- 04 Oct 2018 Accera is now called Cerecin
- 04 Nov 2017 No recent reports of development identified for preclinical development in Huntington's-disease in USA
- 04 Nov 2017 No recent reports of development identified for research development in Parkinson's-disease in USA